ARTICLE | Clinical News
Celldex routed after TNBC failure
April 16, 2018 7:11 PM UTC
Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.39 (65%) to $0.76 on Monday after it said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (2.9 vs. 2.8 months, HR=0.95, p=0.76).
Celldex plans to discontinue the candidate's development for all indications, including breast cancer and melanoma, and said it will review its pipeline...
BCIQ Company Profiles
BCIQ Target Profiles